|
medpundit |
||
 |
 |
|
Friday, September 26, 2003Early trials on 60 patients with cancers of the prostate, breast, liver and colon which had not responded to other cancers showed promising results and demonstrated what the ideal dose was. This means researchers know what dosage to give patients in the next stage of research, which has just started to recruit patients. Ana Ruiz-Casado, a cancer specialist from Pharma Mar in Madrid, who is involved in the research, told BBC News Online: "There are some tumours, such as liver, melanomas and mesotheliomas that we do not have many active drugs that we can use. "So if we have anything, it's better than having nothing." The protein, Kahalalide F, disrupts the digestive system of cancer cells: Kahalalide F alters the function of the lysosomal membrane (part of the internal ‘digestive system’ of a cell), a mechanism that distinguishes it from all other known anti-tumour agents. Studies demonstrate that Kahalalide F induces cell necrosis in vivo (oncosis) and shows selectivity for tumour compared to normal cells in vitro. And it's natural! The man who discovered the protein died earlier this year, but a description of some of his other work is here. There's a wealth of treasure under the sea. posted by Sydney on 9/26/2003 08:02:00 AM 0 comments 0 Comments: |
|
